Injury incidence, severity and type across the menstrual cycle in elite female professional footballers: a prospective three season cohort study - Barlow, Ally; Blodgett, Joanna M; Williams, Sean; Pedlar, Charles R; Bruinvels, Georgie (medRxiv, 2023)
Objectives The aim of the study was to assess the influence of menstrual cycle phase on injury incidence, severity and type in elite female professional footballers over three seasons.Methods Time-loss injuries and menstrual cycle data were prospectively recorded for 26 elite female football players across three seasons. The menstrual cycle was categorised into four phases using a standardised model: menstruation (phase 1; P1), remainder of follicular phase (phase 2; P2), early luteal (phase 3; P3), and pre-menstrual phase (phase 4; P4). Injury incidence rates (IRR) and ratios (IIRR) were calculated for overall injuries, injury type, contact vs non-contact, game/training and severity of injury.Results 593 cycles across 13,390 days were tracked during the study and 74 injuries from 26 players were eligible for analysis. Muscle injuries were the most prevalent sub-type (n=41). When comparing IRR between phases (reference: P1), injury rates were highest in P4 for overall (IIRR: 2.30 [95% CI: 0.99-5.34; p=0.05]), muscle-specific (6.07 [1.34-27.43; p=0.02]), non-contact (3.05 [1.10-8.50; p=0.03]) and ≤7 day’s time-loss injuries (4.40 [0.93-20.76; p=0.06]). Muscle-specific (IIRR P3:P1: 5.07 [1.16-22.07; p=0.03]) and ≤7 day’s time-loss (4.47 [1.01-19.68; p=0.05]) injury risk were also significantly higher in P3. No anterior cruciate ligament injuries were recorded across the monitoring period.Conclusion Injury risk was significantly elevated during the luteal phase of the menstrual cycle (P3 and P4) among elite female professional footballers. Further research is urgently needed to better understand the influence of the menstrual cycle on injury risk and to develop interventions to mitigate risk.What are the new findings?Injury risk was lowest in phase 1, during menstruation.Rate of overall injuries was highest in the luteal phase (phases 3 and 4), specifically for non-contact and lower severity injuries (e.g. 1-7 days missed training).Muscle injury risk increased across the menstrual cycle, with a greater incidence in the luteal phase (phases 3 and 4).Conversely to current perceptions, squad availability is significantly impacted by a wide range of injuries that are related to menstrual cycle phase, not just significant ligament injuries.How might it impact on clinical practice in the near future?When reviewing injury occurrence, mechanism and prevention guidelines, it is crucial to consider menstrual cycle day and phase.Longitudinal menstrual cycle monitoring provides an additional, potentially useful factor to support female athletes.The results of this study demonstrate that there is an urgent need to collect menstrual cycle data alongside standardised injury data to allow for further exploration in a larger sample.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study id not receive fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by MSc SEM (Sports and exercise medicine) & SPY (sports physiotherapy) Research Ethics Approval Committee at the University of Bath.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors